These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9268175)

  • 1. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis.
    Holmström M; Lindmarker P; Granqvist S; Johnsson H; Lockner D
    Thromb Haemost; 1997 Aug; 78(2):803-7. PubMed ID: 9268175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis.
    Holmström M; Aberg W; Lockner D; Paul C
    Thromb Haemost; 1999 Oct; 82(4):1222-6. PubMed ID: 10544902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
    Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
    Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
    Lindmarker P; Holmström M; Granqvist S; Johnsson H; Lockner D
    Thromb Haemost; 1994 Aug; 72(2):186-90. PubMed ID: 7831649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H; Marchetti O; Haeberli A; Mombelli G
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
    Breddin HK; Kadziola Z; Scully M; Nakov R; Misselwitz F; Kakkar VV
    Thromb Haemost; 2003 Feb; 89(2):272-7. PubMed ID: 12574806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.
    Partsch H; Blättler W
    J Vasc Surg; 2000 Nov; 32(5):861-9. PubMed ID: 11054217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
    Lopaciuk S; Meissner AJ; Filipecki S; Zawilska K; Sowier J; Ciesielski L; Bielawiec M; Glowinski S; Czestochowska E
    Thromb Haemost; 1992 Jul; 68(1):14-8. PubMed ID: 1325076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
    Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
    Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
    J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
    Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
    Luomanmäki K; Grankvist S; Hallert C; Jauro I; Ketola K; Kim HC; Kiviniemi H; Koskivirta H; Sörskog L; Vilkko P
    J Intern Med; 1996 Aug; 240(2):85-92. PubMed ID: 8810934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.
    Thromb Haemost; 1991 Mar; 65(3):251-6. PubMed ID: 1646490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practicability and quality of outpatient management of acute deep venous thrombosis.
    Blättler W; Kreis N; Blättler IK
    J Vasc Surg; 2000 Nov; 32(5):855-60. PubMed ID: 11054216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.